We used molecular, genetic and bioinformatic approaches to determine the mechanism of micronuclei formation induced by two TOP1 poisons (CPT and LMP776) in different human cancer cells, including SCLC cell lines.
NAXIVA is the first clinical trial to evaluate neoadjuvant downstaging of patients with the unique biological phenomenon of venous tumour thrombus in kidney cancer. But what did we learn beyond the endpoints?
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us